Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) and Altimmune (NASDAQ:ALT) Financial Contrast

Altimmune (NASDAQ:ALT) and Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Institutional and Insider Ownership

78.1% of Altimmune shares are owned by institutional investors. 4.1% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Altimmune and Telix Pharmaceuticals Limited American Depositary Shares”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$430,000.00	1,040.34	-$88.45 million	($1.55)	-4.06
Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A

Telix Pharmaceuticals Limited American Depositary Shares has lower revenue, but higher earnings than Altimmune.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Altimmune and Telix Pharmaceuticals Limited American Depositary Shares, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	0	1	6	1	3.00
Telix Pharmaceuticals Limited American Depositary Shares	0	0	1	1	3.50

Altimmune presently has a consensus price target of $20.83, indicating a potential upside of 231.21%. Telix Pharmaceuticals Limited American Depositary Shares has a consensus price target of $22.00, indicating a potential upside of 24.72%. Given Altimmune’s higher probable upside, analysts clearly believe Altimmune is more favorable than Telix Pharmaceuticals Limited American Depositary Shares.

Profitability

This table compares Altimmune and Telix Pharmaceuticals Limited American Depositary Shares’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Altimmune	-199,076.92%	-55.81%	-50.60%
Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A

Summary

Altimmune beats Telix Pharmaceuticals Limited American Depositary Shares on 5 of the 9 factors compared between the two stocks.

About Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

About Telix Pharmaceuticals Limited American Depositary Shares

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.